Developer docs
API playgroundTry for free, no card

Search company profiles

InnovHeart

Full company profile

uuid0002fpi

Namestring
InnovHeart
Legal namestring
InnovHeart S.r.l.
Websiteurl
innovheart.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

InnovHeart S.r.l. is an Italy-based, privately held medical device company founded in 2015 by Giovanni Righini, a 30-year veteran of the implantable cardiac device industry, with continuous backing from Genextra S.p.A. The company is developing the Saturn Transcatheter Mitral Valve Replacement (TMVR) system to treat patients suffering from mitral regurgitation, a condition affecting an estimated 4 million people in the US and EU and for which approximately 98% of cases remain untreated due to the invasiveness of conventional surgery. The Saturn platform combines a low-profile bioprosthetic valve with a proprietary annular remodeling structure that anchors through a subannular ring at the base of the left ventricle, intended to eliminate mitral regurgitation while minimizing valve migration, paravalvular leak, LVOT obstruction, and Systolic Anterior Motion.

The core technology supports two delivery approaches — an initial trans-apical pathway, which achieved first-in-human status in August 2020, and a trans-septal delivery system using a 29 French delivery catheter with two valve sizes (28mm and 31mm), which achieved first-in-human implantation in May 2024 as part of the CASSINI-EU Early Feasibility Study. InnovHeart has built ISO 13485:2016 certified quality systems (issued by ACCREDIA) and maintains an intellectual property portfolio anchored by more than 30 patent applications from its founder in transcatheter heart valve replacement, plus 10 medical device patents held by CEO David Wilson.

Commercially, InnovHeart is pre-revenue and investigational-only. Its revenue model, once approvals are obtained, envisions direct hardware sales of the Saturn TMVR system to tertiary and quaternary cardiac centers, complemented by an exclusive licensing agreement with Grand Pharmaceutical Group Limited (closed January 2022) covering development, manufacturing, and commercialization in Greater China, which provides milestone payments and structured royalties alongside the equity financing. Go-to-market relies on enterprise field sales, physician education, key opinion leader engagement at major structural heart conferences (EuroPCR, TCT, NY Valves, TVT, CSI Frankfurt, PCR London Valve), and peer-reviewed publications (JACC Case Reports, Annals of Thoracic Surgery Short Reports, Eurointervention). The company operates from Milan (legal headquarters) and Colleretto Giacosa, Italy, with a US subsidiary (InnovHeart US Inc.) in Newton, Massachusetts.

Short descriptiontext

InnovHeart is an Italy-based, privately held medical device company developing the Saturn Transcatheter Mitral Valve Replacement (TMVR) system to treat mitral regurgitation in high-risk patients unsuitable for conventional surgery. The investigational platform combines a bioprosthetic valve with proprietary annular remodeling architecture, delivered via trans-apical or trans-septal approaches, with commercialization pending regulatory approval.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMilano, Italy
HQ citystring
Milano
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
transcatheter mitral valve, structural heart devices, mitral valve replacement, cardiac medical devices, transseptal delivery systems
Industry2 codes
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHABAG
Interventional Radiology & Image-Guided Therapy Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Transcatheter Mitral Valve Replacement (Structural Heart Devices)
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Product Sales (Future)
TypeHardware Sales
Description

Once commercially approved, InnovHeart plans to generate revenue through direct sales of its Saturn TMVR system to hospitals and cardiac surgery centers. The company currently has an exclusive licensing agreement with Grand Pharmaceutical for Greater China.

innovheart.com
2Licensing Royalties
TypeLicensing Royalties
Description

InnovHeart receives milestone payments and structured royalties from Grand Pharmaceutical Group Limited under the exclusive licensing agreement for Saturn device development and commercialization in Greater China (Mainland China, Hong Kong, Macau, Taiwan).

innovheart.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

InnovHeart develops the Saturn Transcatheter Mitral Valve Replacement (TMVR) System, a novel low-profile prosthetic mitral valve designed for both trans-apical and trans-septal delivery to treat patients with mitral regurgitation. The device features an annular remodeling structure with a subannular ring and a 29 French delivery system, offered in two valve sizes (28mm and 31mm). The product is currently limited to investigational use in clinical trials (CASSINI-EU study) and is not commercially available.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Patient showed reduction from NYHA Class III to NYHA Class II within 30 days post-implant with improved six-minute walk test and KCCQ Quality of Life survey scores
+2 more records
Product overview1 text field

InnovHeart develops a single unified product line centered on the Saturn Transcatheter Mitral Valve Replacement (TMVR) System. The core Saturn platform is a low-profile prosthetic valve designed for both trans-apical and trans-septal delivery approaches, addressing the treatment of mitral regurgitation. The trans-apical version was the first to undergo clinical testing, followed by the trans-septal version which uses the same Saturn valve technology with an updated delivery system. All Saturn products are investigational devices limited to clinical trial use and are not commercially available.

Product and service2 records
1Saturn TMVR System
CategoryTranscatheter Mitral Valve Replacement (Structural Heart)
Description

A novel transcatheter mitral valve replacement (TMVR) system designed for the treatment of mitral regurgitation. The Saturn is a low-profile prosthetic designed for both trans-apical and trans-septal delivery approaches, featuring a bioprosthetic valve with an annular structure that remodels the native annulus and seals the perimeter of the implant. Currently limited to investigational use in clinical trials and not commercially available.

2Saturn Trans-Septal TMVR System
CategoryTranscatheter Mitral Valve Replacement Delivery System
Description

The trans-septal version of the Saturn valve using a 29 French Valve Delivery System with two valve sizes (28 and 31mm). It anchors to the native mitral valve through a subannular ring at the base of the left ventricle, providing mechanical continuity between the bioprosthesis and annular segments. Designed to minimize screen-outs due to unsupported annulus size/shape and left ventricle size, and to minimize risks of valve migration, paravalvular leaks, LVOT obstruction and Systolic Anterior Motion. Currently investigational.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

ENEA Tech e Biomedical supports clinical development of Saturn TMVR system. Video collaboration showcasing company vision and technology development highlights partnership in driving clinical validation.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-01-27
Description

Exclusive licensing agreement for Saturn TMVR device in Greater China (Mainland China, Hong Kong, Macau, Taiwan). Grand Pharma received rights to develop, manufacture, and commercialize the device. Transaction included equity investment, upfront licensing fees, milestone payments and structured royalties totaling over $55 million.

3Dr. Azin Parhizgar, Ph.D.
Strategic tierMinorTypeOthersAnnounced on2021-01-12
Description

Independent Board Member with extensive medical device executive experience. Previously President/CEO of Claret Medical (acquired by Boston Scientific) and held positions at Conor Medsystems (J&J) and AVE (Medtronic).

innovheart.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

HighLife is a European transcatheter mitral valve replacement company developing a trans-septal TMVR system. It is directly comparable to InnovHeart in size, stage, technology category, and target indication (mitral regurgitation via transcatheter replacement).

TypeEmerging player
Description

Cardiac Dimensions develops the Carillon System, a transcatheter mitral annuloplasty device for functional mitral regurgitation. While focused on repair rather than replacement, it is a relevant peer addressing the same mitral regurgitation patient population with a transcatheter approach.

TypeBroad incumbent
Description

Boston Scientific is a major structural heart incumbent (Watchman, ACURATE) with deep relationships with the KOLs that InnovHeart engages (Dr. Keith Dawkins, the InnovHeart Chairman, was formerly EVP/CMO at Boston Scientific). Its commercial scale and acquisition appetite make it both a competitor and a potential strategic acquirer of InnovHeart.

TypeDirect peer
Description

JenaValve is a privately held transcatheter heart valve company focused on TAVR and emerging aortic/mitral applications. It is closely comparable to InnovHeart as a similarly-sized, clinical-stage, venture-backed transcatheter valve developer targeting structural heart indications.

5Neovasc
TypeEmerging player
Description

Neovasc develops transcatheter mitral valve therapies including the Tiara TMVR system and the Neovasc Reducer for refractory angina. It is comparable to InnovHeart as a structural heart specialist pursuing transcatheter mitral replacement with a similar regulatory and clinical pathway.

TypeDirect peer
Description

Medtronic has historically led TMVR development through its Intrepid program and remains a structural heart incumbent with extensive TMVR/surgical mitral valve offerings. Its scale and physician relationships make it the central incumbent InnovHeart must compete with for KOL engagement and eventual market share.

TypeDirect peer
Description

4C Medical is an emerging transcatheter mitral valve company developing the AltaValve TMVR system. It is closely comparable to InnovHeart as a clinical-stage, VC-backed company pursuing TMVR with a differentiated anchoring approach for mitral regurgitation patients.

TypeDirect peer
Description

Edwards Lifesciences is the dominant structural heart company and the most advanced competitor in TMVR with its PASCAL Precision and SAPIEN M3 programs. Both target the same mitral regurgitation patient population as InnovHeart's Saturn and represent the primary competitive benchmark for clinical and commercial success.

TypeDirect peer
Description

LivaNova (formed from the merger of Sorin and Cyberonics) is a direct Italian heritage peer: founder Giovanni Righini previously served as R&D Director at Sorin Group. LivaNova continues to develop heart valve products and provides a useful comparator for an Italian-rooted, valve-focused business expanding into transcatheter technologies.

10Abbott
TypeDirect peer
Description

Abbott developed the Tendyne TMVR system and continues to operate broadly in structural heart through MitraClip and related transcatheter mitral technologies. Its positioning in both repair (MitraClip) and replacement makes it a key benchmark for the TMVR opportunity InnovHeart is pursuing.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

InnovHeart

Transcatheter Mitral Valve Replacement (Structural Heart Devices)innovheart.com

InnovHeart is an Italy-based, privately held medical device company developing the Saturn Transcatheter Mitral Valve Replacement (TMVR) system to treat mitral regurgitation in high-risk patients unsuitable for conventional surgery. The investigational platform combines a bioprosthetic valve with proprietary annular remodeling architecture, delivered via trans-apical or trans-septal approaches, with commercialization pending regulatory approval.

What InnovHeart does

InnovHeart S.r.l. is an Italy-based, privately held medical device company founded in 2015 by Giovanni Righini, a 30-year veteran of the implantable cardiac device industry, with continuous backing from Genextra S.p.A. The company is developing the Saturn Transcatheter Mitral Valve Replacement (TMVR) system to treat patients suffering from mitral regurgitation, a condition affecting an estimated 4 million people in the US and EU and for which approximately 98% of cases remain untreated due to the invasiveness of conventional surgery. The Saturn platform combines a low-profile bioprosthetic valve with a proprietary annular remodeling structure that anchors through a subannular ring at the base of the left ventricle, intended to eliminate mitral regurgitation while minimizing valve migration, paravalvular leak, LVOT obstruction, and Systolic Anterior Motion.

The core technology supports two delivery approaches — an initial trans-apical pathway, which achieved first-in-human status in August 2020, and a trans-septal delivery system using a 29 French delivery catheter with two valve sizes (28mm and 31mm), which achieved first-in-human implantation in May 2024 as part of the CASSINI-EU Early Feasibility Study. InnovHeart has built ISO 13485:2016 certified quality systems (issued by ACCREDIA) and maintains an intellectual property portfolio anchored by more than 30 patent applications from its founder in transcatheter heart valve replacement, plus 10 medical device patents held by CEO David Wilson.

Commercially, InnovHeart is pre-revenue and investigational-only. Its revenue model, once approvals are obtained, envisions direct hardware sales of the Saturn TMVR system to tertiary and quaternary cardiac centers, complemented by an exclusive licensing agreement with Grand Pharmaceutical Group Limited (closed January 2022) covering development, manufacturing, and commercialization in Greater China, which provides milestone payments and structured royalties alongside the equity financing. Go-to-market relies on enterprise field sales, physician education, key opinion leader engagement at major structural heart conferences (EuroPCR, TCT, NY Valves, TVT, CSI Frankfurt, PCR London Valve), and peer-reviewed publications (JACC Case Reports, Annals of Thoracic Surgery Short Reports, Eurointervention). The company operates from Milan (legal headquarters) and Colleretto Giacosa, Italy, with a US subsidiary (InnovHeart US Inc.) in Newton, Massachusetts.

InnovHeart firmographics

Firmographics
Name
InnovHeart
Legal name
InnovHeart S.r.l.
Website
https://innovheart.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
InnovHeart is an Italy-based, privately held medical device company developing the Saturn Transcatheter Mitral Valve Replacement (TMVR) system to treat mitral regurgitation in high-risk patients unsuitable for conventional surgery. The investigational platform combines a bioprosthetic valve with proprietary annular remodeling architecture, delivered via trans-apical or trans-septal approaches, with commercialization pending regulatory approval.
Ownership category
akta.pro rank

InnovHeart industry classification

Industry
Product category
Transcatheter Mitral Valve Replacement (Structural Heart Devices)
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHABAG
Interventional Radiology & Image-Guided Therapy Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment

Keywords

  • Transcatheter mitral valve
  • Structural heart devices
  • Mitral valve replacement
  • Cardiac medical devices
  • Transseptal delivery systems

Where InnovHeart is headquartered

Location

Headquarters

HQ city
Milano
HQ country
Italy
HQ region
Europe

Offices3 records

Markets served

InnovHeart business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Product Sales (Future): Once commercially approved, InnovHeart plans to generate revenue through direct sales of its Saturn TMVR system to hospitals and cardiac surgery centers. The company currently has an exclusive licensing agreement with Grand Pharmaceutical for Greater China.
  2. Licensing Royalties: InnovHeart receives milestone payments and structured royalties from Grand Pharmaceutical Group Limited under the exclusive licensing agreement for Saturn device development and commercialization in Greater China (Mainland China, Hong Kong, Macau, Taiwan).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

InnovHeart product offering

Product offering

Core offering

InnovHeart develops the Saturn Transcatheter Mitral Valve Replacement (TMVR) System, a novel low-profile prosthetic mitral valve designed for both trans-apical and trans-septal delivery to treat patients with mitral regurgitation. The device features an annular remodeling structure with a subannular ring and a 29 French delivery system, offered in two valve sizes (28mm and 31mm). The product is currently limited to investigational use in clinical trials (CASSINI-EU study) and is not commercially available.

Product overview

InnovHeart develops a single unified product line centered on the Saturn Transcatheter Mitral Valve Replacement (TMVR) System. The core Saturn platform is a low-profile prosthetic valve designed for both trans-apical and trans-septal delivery approaches, addressing the treatment of mitral regurgitation. The trans-apical version was the first to undergo clinical testing, followed by the trans-septal version which uses the same Saturn valve technology with an updated delivery system. All Saturn products are investigational devices limited to clinical trial use and are not commercially available.

Differentiator

Problem solved

Functional benefit

Products and services

  • Saturn TMVR System A novel transcatheter mitral valve replacement (TMVR) system designed for the treatment of mitral regurgitation. The Saturn is a low-profile prosthetic designed for both trans-apical and trans-septal delivery approaches, featuring a bioprosthetic valve with an annular structure that remodels the native annulus and seals the perimeter of the implant. Currently limited to investigational use in clinical trials and not commercially available.
  • Saturn Trans-Septal TMVR System The trans-septal version of the Saturn valve using a 29 French Valve Delivery System with two valve sizes (28 and 31mm). It anchors to the native mitral valve through a subannular ring at the base of the left ventricle, providing mechanical continuity between the bioprosthesis and annular segments. Designed to minimize screen-outs due to unsupported annulus size/shape and left ventricle size, and to minimize risks of valve migration, paravalvular leaks, LVOT obstruction and Systolic Anterior Motion. Currently investigational.

Quantifiable outcome

  • Patient showed reduction from NYHA Class III to NYHA Class II within 30 days post-implant with improved six-minute walk test and KCCQ Quality of Life survey scores
  • +2 more outcomes

Companies that use InnovHeart

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles1 record

InnovHeart technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

InnovHeart partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • ENEA Tech e BiomedicalcoreStrategic or Co-development Partner · 1 October 2025ENEA Tech e Biomedical supports clinical development of Saturn TMVR system. Video collaboration showcasing company vision and technology development highlights partnership in driving clinical validation.
  • Grand Pharmaceutical Group LimitedcoreOEM/ Whitelabel/ Licensing Partner · 27 January 2022Exclusive licensing agreement for Saturn TMVR device in Greater China (Mainland China, Hong Kong, Macau, Taiwan). Grand Pharma received rights to develop, manufacture, and commercialize the device. Transaction included equity investment, upfront licensing fees, milestone payments and structured royalties totaling over $55 million.
  • Dr. Azin Parhizgar, Ph.D.minorOthers · 12 January 2021Independent Board Member with extensive medical device executive experience. Previously President/CEO of Claret Medical (acquired by Boston Scientific) and held positions at Conor Medsystems (J&J) and AVE (Medtronic).

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

InnovHeart competitors and assessment

Company assessment

Direct peers

  • HighLife SAS: HighLife is a European transcatheter mitral valve replacement company developing a trans-septal TMVR system. It is directly comparable to InnovHeart in size, stage, technology category, and target indication (mitral regurgitation via transcatheter replacement).
  • JenaValve Technology: JenaValve is a privately held transcatheter heart valve company focused on TAVR and emerging aortic/mitral applications. It is closely comparable to InnovHeart as a similarly-sized, clinical-stage, venture-backed transcatheter valve developer targeting structural heart indications.
  • Medtronic: Medtronic has historically led TMVR development through its Intrepid program and remains a structural heart incumbent with extensive TMVR/surgical mitral valve offerings. Its scale and physician relationships make it the central incumbent InnovHeart must compete with for KOL engagement and eventual market share.
  • 4C Medical Technologies: 4C Medical is an emerging transcatheter mitral valve company developing the AltaValve TMVR system. It is closely comparable to InnovHeart as a clinical-stage, VC-backed company pursuing TMVR with a differentiated anchoring approach for mitral regurgitation patients.
  • Edwards Lifesciences: Edwards Lifesciences is the dominant structural heart company and the most advanced competitor in TMVR with its PASCAL Precision and SAPIEN M3 programs. Both target the same mitral regurgitation patient population as InnovHeart's Saturn and represent the primary competitive benchmark for clinical and commercial success.
  • LivaNova: LivaNova (formed from the merger of Sorin and Cyberonics) is a direct Italian heritage peer: founder Giovanni Righini previously served as R&D Director at Sorin Group. LivaNova continues to develop heart valve products and provides a useful comparator for an Italian-rooted, valve-focused business expanding into transcatheter technologies.
  • Abbott: Abbott developed the Tendyne TMVR system and continues to operate broadly in structural heart through MitraClip and related transcatheter mitral technologies. Its positioning in both repair (MitraClip) and replacement makes it a key benchmark for the TMVR opportunity InnovHeart is pursuing.

Emerging players

  • Cardiac Dimensions: Cardiac Dimensions develops the Carillon System, a transcatheter mitral annuloplasty device for functional mitral regurgitation. While focused on repair rather than replacement, it is a relevant peer addressing the same mitral regurgitation patient population with a transcatheter approach.
  • Neovasc: Neovasc develops transcatheter mitral valve therapies including the Tiara TMVR system and the Neovasc Reducer for refractory angina. It is comparable to InnovHeart as a structural heart specialist pursuing transcatheter mitral replacement with a similar regulatory and clinical pathway.

Broad incumbents

  • Boston Scientific: Boston Scientific is a major structural heart incumbent (Watchman, ACURATE) with deep relationships with the KOLs that InnovHeart engages (Dr. Keith Dawkins, the InnovHeart Chairman, was formerly EVP/CMO at Boston Scientific). Its commercial scale and acquisition appetite make it both a competitor and a potential strategic acquirer of InnovHeart.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

InnovHeart compliance and trust

Trust signal

Compliance1 record

InnovHeart financial estimates

Financial estimate

Revenue estimate

Valuation estimate

InnovHeart leadership team

Management profile

Number of profiles

Profiles8 records

InnovHeart subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

InnovHeart funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

InnovHeart M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InnovHeart

What does InnovHeart do?

InnovHeart develops the Saturn Transcatheter Mitral Valve Replacement (TMVR) System, a novel low-profile prosthetic mitral valve designed for both trans-apical and trans-septal delivery to treat patients with mitral regurgitation. The device features an annular remodeling structure with a subannular ring and a 29 French delivery system, offered in two valve sizes (28mm and 31mm). The product is currently limited to investigational use in clinical trials (CASSINI-EU study) and is not commercially available.

Is InnovHeart a public or private company?

InnovHeart is a private company. It is classified as venture growth investor backed and is currently operating.

When was InnovHeart founded?

InnovHeart was founded in 2015. It employs 11 to 50 people.

Where is InnovHeart based?

InnovHeart is headquartered in Milano, Italy, in the Europe region.

How does InnovHeart make money?

Two revenue lines are on record. Product Sales (Future) is the primary driver. The others are licensing Royalties.

Who are InnovHeart's main competitors?

Direct peers on record are HighLife SAS, JenaValve Technology, Medtronic, 4C Medical Technologies, Edwards Lifesciences, LivaNova and Abbott. Emerging players are Cardiac Dimensions and Neovasc. Boston Scientific is listed as a broad incumbent.

Does InnovHeart have an API?

No public API is recorded for InnovHeart.

What industry is InnovHeart in?

InnovHeart's product category is Transcatheter Mitral Valve Replacement (Structural Heart Devices). Its primary akta.pro industry code is HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair, with a secondary code of HLAHABAG, Interventional Radiology & Image-Guided Therapy Systems. Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AInvestInnovHeart's 15th TMVR Patient Is a Clinical Milestone. The Investment Story Belongs to Edwards.InnovHeart implanted its first U.S. patient with the Saturn transcatheter mitral valve replacement system on August 25, reaching 15 patients globally. Edwards Lifesciences' SAPIEN M3 is already FDA-approved, with the TMVR market projected to grow from $1.65 billion in 2024 to $5.47 billion by 2029. InnovHeart remains privately held, while Edwards targets $2 billion in TMVR sales by 2030.MorningstarInnovHeart Announces First U.S. Saturn Transseptal TMVR System Implant, Reaching 15 Patients GloballyInnovHeart implanted the first U.S. patient with its Saturn Transseptal TMVR system on August 25 at NewYork-Presbyterian/Columbia, an 86-year-old female with severe mitral regurgitation. The procedure succeeded with no LVOT obstruction and elimination of regurgitation. The company now has 15 patients treated globally in the CASSINI program.PR NewswireInnovHeart Announces First U.S. Saturn Transseptal TMVR System Implant, Reaching 15 Patients GloballyInnovHeart implanted the first U.S. patient with its Saturn Transseptal TMVR system on August 25 at NewYork-Presbyterian/Columbia, an 86-year-old female with severe mitral regurgitation. The procedure succeeded with no LVOT obstruction and elimination of regurgitation. The company now has 15 patients treated globally, with follow-up exceeding two years.PR NewswireInnovHeart Announces First-In-Human Trans-Septal Implantation of Saturn Mitral Valve ReplacementInnovHeart s.r.l. announced the first trans-septal clinical trial implantation of its Saturn Transcatheter Mitral Valve Replacement system on May 8, 2024, at Santaros Klinikos University Hospital in Vilnius, Lithuania, achieving excellent hemodynamic results in a 79-year-old female patient with severe mixed mitral regurgitation. The successful procedure validates that the Saturn valve can be delivered via a fully percutaneous, transfemoral transseptal approach, marking a significant advancement beyond the company's initial trans-apical method. The CASSINI-EU study will expand to multiple countries and enroll up to 30 patients with moderate to severe or severe mitral regurgitation.FierceBiotechInnovHeart nabs J&J, Haemonetics alum to lead mitral system maker as CEOInnovHeart appointed David Wilson as CEO to lead its transseptal Saturn transcatheter mitral valve replacement system into clinical trials. The company recently closed a $55 million funding round, and the system could compete with Abbott and Medtronic devices if approved. Wilson brings experience from Haemonetics and Johnson & Johnson.BioSpaceInnovHeart raises $55 million in Series C financing to further develop the Trans-septal Saturn Transcatheter Mitral Valve Replacement SystemInnovHeart s.r.l., a developer of transcatheter mitral valve replacement systems, closed a Series C financing round on Jan. 27, 2022, led by Grand Pharma with existing investors Genextra, Panakes Partners and Indaco Venture Partners. The deal raised more than $55 million in equity, upfront licensing fees, milestone payments and structured royalties, with Grand Pharma licensing the Saturn device for Mainland China, Hong Kong, Macau and Taiwan. The trans-septal version is planned for first-in-human trials in 2022.Venture Capital Access OnlineInnovHeart raises $55 million in Series C financing to further develop the Trans-septal Saturn Transcatheter Mitral Valve Replacement SystemInnovHeart announced the closing of a $55 million Series C financing round led by Grand Pharmaceutical Group, alongside existing investors Genextra, Panakes Partners, and Indaco Venture Partners. The transaction included an exclusive license agreement granting Grand Pharma rights to develop and commercialize InnovHeart's Saturn TMVR device in Greater China. This funding is intended to accelerate the development of the trans-septal version of the Saturn system into First-in-Human clinical trials.PR NewswireAzin Parhizgar, Ph.D. Joins InnovHeart as Independent Member of the Board of DirectorsInnovHeart s.r.l. appointed Dr. Azin Parhizgar, Ph.D. as an Independent Member of the Board of Directors. Dr. Parhizgar brings extensive experience in the medical device industry, having led multiple cardiovascular start-ups and overseen significant acquisitions. InnovHeart is advancing the clinical development of its Saturn Transcatheter Mitral Valve Replacement system, aiming to enhance treatment for mitral valve disease.PR NewswireInnovHeart Reports Successful First-in-Human Implantation of its Saturn Transcatheter Mitral Valve with Excellent 30-day Follow-upInnovHeart s.r.l. announced the successful first-in-human implantation of its Saturn Transcatheter Mitral Valve Replacement system on August 19, 2020, at Santaros Klinikos University Hospital in Vilnius, Lithuania, as part of an ongoing European clinical trial. The 72-year-old patient showed excellent 30-day follow-up results with significant symptom reduction, improvement in quality-of-life measures, and outstanding valve hemodynamic performance with no mitral regurgitation. The company is continuing enrollment in its European Trans-Apical Pilot Study while developing a trans-septal delivery system.PR NewswireInnovHeart Appoints Brent Ratz as Independent member of the boardInnovHeart s.r.l., a Milan-based developer of transcatheter mitral valve replacement systems, appointed J. Brent Ratz as an independent non-executive member of its Board of Directors. Ratz brings over 19 years of medical device industry experience, including serving as founding CEO of CardiAQ Valve Technologies, which was acquired by Edwards Lifesciences for $400 million in 2015, and currently serving as co-founder and Managing Director of inQB8 Medical Technologies. The appointment is intended to support the development of InnovHeart's Saturn TMVR technology for treating mitral valve disease.